FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000325856> ?p ?o ?g. }

• W2000325856 endingPage "202" @default.
• W2000325856 startingPage "197" @default.
• W2000325856 abstract "Purpose To identify factors associated with grade ≥3 treatment related late esophageal toxicity after lung or liver stereotactic body radiation therapy (SBRT). Methods and Materials This was a retrospective review of 52 patients with a planning target volume within 2 cm of the esophagus from a prospective registry of 607 lung and liver SBRT patients treated between 2005 and 2011. Patients were treated using a risk-adapted dose regimen to a median dose of 50 Gy in 5 fractions (range, 37.5-60 Gy in 3-10 fractions). Normal structures were contoured using Radiation Therapy Oncology Group (RTOG) defined criteria. Results The median esophageal point dose and 1-cc dose were 32.3 Gy (range, 8.9-55.4 Gy) and 24.0 Gy (range, 7.8-50.9 Gy), respectively. Two patients had an esophageal fistula at a median of 8.4 months after SBRT, with maximum esophageal point doses of 51.5 and 52 Gy, and 1-cc doses of 48.1 and 50 Gy, respectively. These point and 1-cc doses were exceeded by 9 and 2 patients, respectively, without a fistula. The risk of a fistula for point doses exceeding 40, 45, and 50 Gy was 9.5% (n=2/21), 10.5% (n=2/19), and 12.5% (n=2/16), respectively. The risk of fistula for 1-cc doses exceeding 40, 45, and 50 Gy was 25% (n=2/9), 50% (n=2/4), and 50% (n=2/4), respectively. Eighteen patients received systemic therapy after SBRT (11 systemic chemotherapy, and 6 biologic agents, and 1 both). Both patients with fistulas had received adjuvant anti-angiogenic (vascular endothelial growth factor) agents within 2 months of completing SBRT. No patient had a fistula in the absence of adjuvant VEGF-modulating agents. Conclusions Esophageal fistula is a rare complication of SBRT. In this series, fistula was seen with esophageal point doses exceeding 51 Gy and 1-cc doses greater than 48 Gy. Notably, however, fistula was seen only in those patients who also received adjuvant VEGF-modulating agents after SBRT. The potential interaction of dose and adjuvant therapy should be considered when delivering SBRT near the esophagus. To identify factors associated with grade ≥3 treatment related late esophageal toxicity after lung or liver stereotactic body radiation therapy (SBRT). This was a retrospective review of 52 patients with a planning target volume within 2 cm of the esophagus from a prospective registry of 607 lung and liver SBRT patients treated between 2005 and 2011. Patients were treated using a risk-adapted dose regimen to a median dose of 50 Gy in 5 fractions (range, 37.5-60 Gy in 3-10 fractions). Normal structures were contoured using Radiation Therapy Oncology Group (RTOG) defined criteria. The median esophageal point dose and 1-cc dose were 32.3 Gy (range, 8.9-55.4 Gy) and 24.0 Gy (range, 7.8-50.9 Gy), respectively. Two patients had an esophageal fistula at a median of 8.4 months after SBRT, with maximum esophageal point doses of 51.5 and 52 Gy, and 1-cc doses of 48.1 and 50 Gy, respectively. These point and 1-cc doses were exceeded by 9 and 2 patients, respectively, without a fistula. The risk of a fistula for point doses exceeding 40, 45, and 50 Gy was 9.5% (n=2/21), 10.5% (n=2/19), and 12.5% (n=2/16), respectively. The risk of fistula for 1-cc doses exceeding 40, 45, and 50 Gy was 25% (n=2/9), 50% (n=2/4), and 50% (n=2/4), respectively. Eighteen patients received systemic therapy after SBRT (11 systemic chemotherapy, and 6 biologic agents, and 1 both). Both patients with fistulas had received adjuvant anti-angiogenic (vascular endothelial growth factor) agents within 2 months of completing SBRT. No patient had a fistula in the absence of adjuvant VEGF-modulating agents. Esophageal fistula is a rare complication of SBRT. In this series, fistula was seen with esophageal point doses exceeding 51 Gy and 1-cc doses greater than 48 Gy. Notably, however, fistula was seen only in those patients who also received adjuvant VEGF-modulating agents after SBRT. The potential interaction of dose and adjuvant therapy should be considered when delivering SBRT near the esophagus." @default.
• W2000325856 created "2016-06-24" @default.
• W2000325856 creator A5001335930 @default.
• W2000325856 creator A5016076582 @default.
• W2000325856 creator A5020128398 @default.
• W2000325856 creator A5025489064 @default.
• W2000325856 creator A5038528892 @default.
• W2000325856 creator A5062476184 @default.
• W2000325856 creator A5063411006 @default.
• W2000325856 creator A5073148665 @default.
• W2000325856 creator A5089460717 @default.
• W2000325856 date "2014-09-01" @default.
• W2000325856 modified "2023-09-24" @default.
• W2000325856 title "Esophageal Dose Tolerance to Hypofractionated Stereotactic Body Radiation Therapy: Risk Factors for Late Toxicity" @default.
• W2000325856 cites W1539022674 @default.
• W2000325856 cites W1975654274 @default.
• W2000325856 cites W1976228480 @default.
• W2000325856 cites W1976563098 @default.
• W2000325856 cites W1981346821 @default.
• W2000325856 cites W2024121508 @default.
• W2000325856 cites W2026514934 @default.
• W2000325856 cites W2034427512 @default.
• W2000325856 cites W2038406853 @default.
• W2000325856 cites W2047037517 @default.
• W2000325856 cites W2068742866 @default.
• W2000325856 cites W2077096883 @default.
• W2000325856 cites W2080399711 @default.
• W2000325856 cites W2107814019 @default.
• W2000325856 cites W2115646671 @default.
• W2000325856 cites W2143022948 @default.
• W2000325856 cites W2159746573 @default.
• W2000325856 cites W2162134154 @default.
• W2000325856 cites W2171180669 @default.
• W2000325856 doi "https://doi.org/10.1016/j.ijrobp.2014.05.011" @default.
• W2000325856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25015204" @default.
• W2000325856 hasPublicationYear "2014" @default.
• W2000325856 type Work @default.
• W2000325856 sameAs 2000325856 @default.
• W2000325856 citedByCount "61" @default.
• W2000325856 countsByYear W20003258562014 @default.
• W2000325856 countsByYear W20003258562015 @default.
• W2000325856 countsByYear W20003258562016 @default.
• W2000325856 countsByYear W20003258562017 @default.
• W2000325856 countsByYear W20003258562018 @default.
• W2000325856 countsByYear W20003258562019 @default.
• W2000325856 countsByYear W20003258562020 @default.
• W2000325856 countsByYear W20003258562021 @default.
• W2000325856 countsByYear W20003258562022 @default.
• W2000325856 countsByYear W20003258562023 @default.
• W2000325856 crossrefType "journal-article" @default.
• W2000325856 hasAuthorship W2000325856A5001335930 @default.
• W2000325856 hasAuthorship W2000325856A5016076582 @default.
• W2000325856 hasAuthorship W2000325856A5020128398 @default.
• W2000325856 hasAuthorship W2000325856A5025489064 @default.
• W2000325856 hasAuthorship W2000325856A5038528892 @default.
• W2000325856 hasAuthorship W2000325856A5062476184 @default.
• W2000325856 hasAuthorship W2000325856A5063411006 @default.
• W2000325856 hasAuthorship W2000325856A5073148665 @default.
• W2000325856 hasAuthorship W2000325856A5089460717 @default.
• W2000325856 hasConcept C121608353 @default.
• W2000325856 hasConcept C126322002 @default.
• W2000325856 hasConcept C126838900 @default.
• W2000325856 hasConcept C2776341189 @default.
• W2000325856 hasConcept C2777819096 @default.
• W2000325856 hasConcept C2779742542 @default.
• W2000325856 hasConcept C2781413609 @default.
• W2000325856 hasConcept C29730261 @default.
• W2000325856 hasConcept C2989005 @default.
• W2000325856 hasConcept C509974204 @default.
• W2000325856 hasConcept C71924100 @default.
• W2000325856 hasConceptScore W2000325856C121608353 @default.
• W2000325856 hasConceptScore W2000325856C126322002 @default.
• W2000325856 hasConceptScore W2000325856C126838900 @default.
• W2000325856 hasConceptScore W2000325856C2776341189 @default.
• W2000325856 hasConceptScore W2000325856C2777819096 @default.
• W2000325856 hasConceptScore W2000325856C2779742542 @default.
• W2000325856 hasConceptScore W2000325856C2781413609 @default.
• W2000325856 hasConceptScore W2000325856C29730261 @default.
• W2000325856 hasConceptScore W2000325856C2989005 @default.
• W2000325856 hasConceptScore W2000325856C509974204 @default.
• W2000325856 hasConceptScore W2000325856C71924100 @default.
• W2000325856 hasIssue "1" @default.
• W2000325856 hasLocation W20003258561 @default.
• W2000325856 hasLocation W20003258562 @default.
• W2000325856 hasOpenAccess W2000325856 @default.
• W2000325856 hasPrimaryLocation W20003258561 @default.
• W2000325856 hasRelatedWork W1975840453 @default.
• W2000325856 hasRelatedWork W2014435840 @default.
• W2000325856 hasRelatedWork W2084845148 @default.
• W2000325856 hasRelatedWork W2275543989 @default.
• W2000325856 hasRelatedWork W2353164399 @default.
• W2000325856 hasRelatedWork W2373333117 @default.
• W2000325856 hasRelatedWork W2384708512 @default.
• W2000325856 hasRelatedWork W2389086225 @default.
• W2000325856 hasRelatedWork W2409129447 @default.
• W2000325856 hasRelatedWork W2473820311 @default.
• W2000325856 hasVolume "90" @default.
• W2000325856 isParatext "false" @default.

• next